PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-15.05%
Negative ROE while Healthcare median is -4.47%. Seth Klarman would investigate if capital structure or industry issues are at play.
-8.76%
Negative ROA while Healthcare median is -5.53%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-10.90%
Negative ROCE while Healthcare median is -5.43%. Seth Klarman would investigate whether a turnaround is viable.
-41.23%
Negative gross margin while Healthcare median is 38.26%. Seth Klarman would check if the firm is selling below cost.
-9904.39%
Negative operating margin while Healthcare median is 0.00%. Seth Klarman would look for a path to operational turnaround.
-8774.56%
Negative net margin while Healthcare median is 0.00%. Seth Klarman would see if cost cuts or revenue growth can fix losses.